Brookstone Capital Management Bristol Myers Squibb CO Transaction History

Brookstone Capital Management

$6.01 Billion
Q3 2024

A detailed history of Brookstone Capital Management transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Brookstone Capital Management holds 167,639 shares of BMY stock, worth $8.92 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

167,639

Previous 150,895 11.1%

Holding current value

$8.92 Million

Previous $6.27 Million 38.45%

% of portfolio

0.14%

Previous 0.12%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	BUY	$39.66 - $51.75 $664,067 - $866,502	16,744 Added 11.1%	167,639 $8.68 Million
Q2 2024 Jul 18, 2024	BUY	$40.25 - $52.99 $34,534 - $45,465	858 Added 0.57%	150,895 $6.27 Million
Q1 2024 Apr 15, 2024	BUY	$47.98 - $54.4 $1.92 Million - $2.18 Million	40,018 Added 36.37%	150,037 $8.14 Million
Q4 2023 Jan 11, 2024	BUY	$48.48 - $57.85 $703,735 - $839,750	14,516 Added 15.2%	110,019 $5.65 Million
Q3 2023 Oct 20, 2023	BUY	$57.89 - $64.73 $3.63 Million - $4.06 Million	62,766 Added 191.73%	95,503 $5.54 Million
Q2 2023 Jul 11, 2023	SELL	$63.71 - $70.74 $54,280 - $60,270	-852 Reduced 2.54%	32,737 $2.09 Million
Q1 2023 Apr 18, 2023	SELL	$65.71 - $74.53 $89,825 - $101,882	-1,367 Reduced 3.91%	33,589 $2.33 Million
Q4 2022 Jan 09, 2023	BUY	$68.48 - $81.09 $57,934 - $68,602	846 Added 2.48%	34,956 $0
Q3 2022 Oct 13, 2022	SELL	$0.13 - $76.84 $2,590 - $1.53 Million	-19,927 Reduced 36.88%	34,110 $2.36 Million
Q2 2022 Jul 11, 2022	SELL	$72.62 - $79.98 $4.1 Million - $4.52 Million	-56,481 Reduced 51.11%	54,037 $4.07 Million
Q1 2022 Apr 12, 2022	BUY	$61.48 - $73.72 $1.07 Million - $1.29 Million	17,451 Added 18.75%	110,518 $8.46 Million
Q4 2021 Jan 11, 2022	SELL	$53.63 - $62.52 $97,982 - $114,224	-1,827 Reduced 1.93%	93,067 $5.85 Million
Q3 2021 Nov 03, 2021	BUY	$59.17 - $69.31 $760,748 - $891,118	12,857 Added 15.67%	94,894 $5.42 Million
Q2 2021 Jul 14, 2021	BUY	$61.91 - $67.42 $1.11 Million - $1.21 Million	18,005 Added 28.12%	82,037 $5.53 Million
Q1 2021 Apr 16, 2021	BUY	$59.34 - $66.74 $325,776 - $366,402	5,490 Added 9.38%	64,032 $4.04 Million
Q4 2020 Jan 13, 2021	SELL	$57.74 - $65.43 $144,985 - $164,294	-2,511 Reduced 4.11%	58,542 $3.63 Million
Q3 2020 Oct 13, 2020	BUY	$57.43 - $63.64 $672,907 - $745,669	11,717 Added 23.75%	61,053 $3.68 Million
Q2 2020 Jul 21, 2020	SELL	$54.82 - $64.09 $488,555 - $571,170	-8,912 Reduced 15.3%	49,336 $2.9 Million
Q1 2020 Apr 14, 2020	SELL	$46.4 - $67.43 $1.23 Million - $1.78 Million	-26,463 Reduced 31.24%	58,248 $3.25 Million
Q4 2019 Jan 29, 2020	BUY	$49.21 - $64.19 $43,600 - $56,872	886 Added 1.06%	84,711 $5.44 Million
Q3 2019 Oct 18, 2019	BUY	$42.77 - $50.71 $1.11 Million - $1.32 Million	26,062 Added 45.12%	83,825 $4.25 Million
Q2 2019 Jul 25, 2019	BUY	$44.62 - $49.34 $2.03 Million - $2.25 Million	45,519 Added 371.77%	57,763 $2.62 Million
Q1 2019 Apr 18, 2019	BUY	$45.12 - $53.8 $33,479 - $39,919	742 Added 6.45%	12,244 $584,000
Q4 2018 Feb 06, 2019	SELL	$48.76 - $63.23 $59,682 - $77,393	-1,224 Reduced 9.62%	11,502 $598,000
Q3 2018 Nov 05, 2018	BUY	$55.19 - $62.25 $54,251 - $61,191	983 Added 8.37%	12,726 $790,000
Q2 2018 Aug 06, 2018	SELL	$50.53 - $62.98 $4,092 - $5,101	-81 Reduced 0.69%	11,743 $650,000
Q1 2018 Apr 23, 2018	BUY	$59.92 - $68.98 $34,334 - $39,525	573 Added 5.09%	11,824 $748,000
Q4 2017 Feb 07, 2018	BUY	$59.94 - $65.35 $15,344 - $16,729	256 Added 2.33%	11,251 $689,000
Q3 2017 Oct 31, 2017	BUY	$55.23 - $63.74 $1,215 - $1,402	22 Added 0.2%	10,995 $701,000
Q2 2017 Aug 08, 2017	BUY	N/A	10,973	10,973 $611,000

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brookstone Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Brookstone Capital Management with notifications on news.

Account

Brookstone Capital Management Bristol Myers Squibb CO Transaction History